Early observations and pilot data that first suggested a new direction
The SYNTAX trial, published in 2009, was the largest randomized comparison of PCI versus CABG for complex coronary artery disease. Among 1,800 patients with three-vessel or left main disease randomized to PCI with paclitaxel-eluting stents or CABG, the 12-month composite of death, stroke, MI, or repeat revascularization was significantly higher with PCI (17.8% vs 12.4%, p=0.002). The difference was driven primarily by increased repeat revascularization with PCI (13.5% vs 5.9%). Notably, stroke risk was higher with CABG. The SYNTAX score emerged as a critical tool for stratifying patients by anatomical complexity.
Landmark RCTs and pivotal trials that established the evidence base
The FREEDOM trial provided definitive evidence for diabetic patients with multivessel disease. Among 1,900 patients with diabetes randomized to PCI with drug-eluting stents or CABG, 5-year rates of the composite primary endpoint (death, MI, or stroke) were significantly lower with CABG (18.7% vs 26.6%). This benefit was driven by reduced MI (p<0.001) and mortality (p=0.049), though stroke was more frequent with CABG (5.2% vs 2.4%, p=0.03). The EXCEL trial, which randomized 1,905 patients with left main disease and low-to-intermediate SYNTAX scores, found PCI noninferior to CABG at 3 years (15.4% vs 14.7%). However, 5-year data revealed divergent outcomes depending on MI definition used, generating significant controversy.
Follow-up studies, subgroup analyses, and real-world validation
The ISCHEMIA trial, published in 2020, challenged prevailing assumptions about the benefit of invasive revascularization in stable ischemic heart disease. Among 5,179 patients with moderate-to-severe ischemia randomized to an initial invasive strategy (PCI or CABG plus medical therapy) versus conservative medical therapy alone, there was no significant difference in the composite primary endpoint of cardiovascular death, MI, hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest (HR 0.93, 95% CI 0.80-1.08, p=0.34) after median 3.2-year follow-up. This finding reinforced that optimal medical therapy remains the foundation of treatment.
Integration into clinical practice guidelines and recommendations
Current guidelines from ACC/AHA and ESC/EACTS recommend Heart Team discussion for all patients with multivessel or left main disease. CABG is generally preferred for patients with high anatomical complexity (SYNTAX score >32), diabetes with multivessel disease, or left main with additional complex disease. PCI remains appropriate for lower complexity anatomy and when surgical risk is prohibitive.
ESC/EACTS
CABG preferred for three-vessel disease with high SYNTAX scores (>22); Heart Team decision for left main and intermediate complexity
ACC/AHA
CABG preferred for diabetic patients with multivessel disease; Heart Team approach for left main disease
Now
Current standard of care and ongoing research directions
The decision between CABG and PCI is increasingly nuanced, guided by the SYNTAX score, diabetic status, completeness of revascularization, and patient preference. The ISCHEMIA trial has reinforced the primacy of optimal medical therapy, with revascularization reserved for symptomatic benefit or prognostic advantage in specific anatomical subsets. Ongoing debates center on the long-term durability of PCI with contemporary drug-eluting stents, the role of fractional flow reserve-guided PCI, and whether functional testing can better identify patients who derive mortality benefit from revascularization.
In which patients is CABG clearly superior to PCI?+
Based on the FREEDOM and SYNTAX trials, CABG demonstrated clear superiority in diabetic patients with multivessel disease (FREEDOM: 5-year composite 18.7% vs 26.6%) and in patients with high anatomical complexity as defined by SYNTAX score >32. The survival benefit of CABG in these populations was driven by reduced MI and mortality.
What did the ISCHEMIA trial show about revascularization in stable coronary disease?+
The ISCHEMIA trial (5,179 patients) found no significant difference in the composite of cardiovascular death, MI, or hospitalization between initial invasive and conservative strategies in stable ischemic heart disease (HR 0.93, p=0.34). This established that optimal medical therapy is the appropriate first-line approach for stable patients, with revascularization reserved for refractory symptoms or specific high-risk anatomy.
